Elicio Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2025, on August 7, 2025. The company announced a net loss of $10.6 million for the quarter, compared to $7.2 million for the second quarter of 2024. The net loss per share for the second quarter of 2025 was $0.66, compared to $0.64 for the same period in the prior year.
Research and development (R&D) expenses for the second quarter of 2025 decreased to $7.0 million from $8.2 million in the second quarter of 2024, primarily due to less clinical trial manufacturing as ELI-002 7P clinical development advanced. General and administrative (G&A) expenses increased to $3.1 million from $2.7 million, mainly due to higher professional fees related to the June 2025 Promissory Note Financing.
As of June 30, 2025, Elicio had $22.1 million in cash and cash equivalents. The company expects its current cash position to support operations into the first quarter of 2026, extending beyond the anticipated AMPLIFY-7P Phase 2 final analysis. This quarter's highlights included a positive recommendation from the IDMC to continue the ELI-002 7P randomized Phase 2 study and the securing of $10 million in financing.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.